{"id":"nct:NCT04977024","kind":"trial","title":"SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer","authors":["GeoVax, Inc."],"author_count":1,"year":2021,"published":"2021-07-26","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT04977024","source_url":"https://clinicaltrials.gov/study/NCT04977024","archive_url":"https://space-kitty.com/papers/nct:NCT04977024","updated":"2026-02-11","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"This phase 2 trial studies the immune response to GEO-CM04S1 (previously designated as COH04S1) compared to standard of care (SOC) mRNA SARS-COV-2 vaccine in patients with blood cancer who have received stem cell transplant or cellular therapy. GEO-CM04S1 belongs to a category called modified vaccinia Ankara (MVA) vaccines, created from a new version of MVA, called synthetic MVA. GEO-CM04S1 works by inducing immunity (the ability to recognize and fight against an infection) to SARS-CoV-2. The immune system is stimulated to produce antibodies against SARS-CoV-2 that would block the virus from entering healthy cells. The immune system also grows new disease fighting T cells that can recognize and destroy infected cells. Giving GEO-CM04S1 after cellular therapy may work better in reducing the chances of contracting coronavirus disease 2019 (COVID-19) or developing a severe form of COVID-19 disease in patients with blood cancer compared to SOC mRNA SARS-CoV-2 vaccine.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["COVID-19 Infection","Hematopoietic and Lymphoid System Neoplasm","Leukemia","Lymphoma","Plasma Cell Myeloma"],"details":{"acronym":null,"status":"ACTIVE_NOT_RECRUITING","phase":"PHASE2","study_type":"INTERVENTIONAL","enrollment":63,"sponsor":"GeoVax, Inc.","conditions":["COVID-19 Infection","Hematopoietic and Lymphoid System Neoplasm","Leukemia","Lymphoma","Plasma Cell Myeloma"],"interventions":["BIOLOGICAL: COVID-19 Vaccine","OTHER: Diagnostic Laboratory Biomarker Analysis","BIOLOGICAL: Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1"],"start_date":"2021-09-27","start_date_type":"ACTUAL","primary_completion_date":"2026-12-31","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"mrna-cancer-vaccines","name":"mRNA Therapeutics & Cancer Vaccines","domain_slug":"medicine"}],"cited_in_dossiers":[]}